Health Plan Best Practices for the Evolving Management of Atopic Dermatitis

Learn About:

• Atopic dermatitis treatment landscapes and challenges
• Health plan best practices for the management of atopic dermatitis
• Strategies that address barriers to care

Expert Faculty Presenters:

Steven S. Kheloussi, PharmD, MBA Adjunct Professor of Pharmacy Practice Wilkes University Click here for biography Dana McCormick, RPh, FAMCP Director of Pharmacy Blue Cross Blue Shield of Texas Click here for biography Jennifer Schoch, MD, FAAD Associate Professor Pediatric Dermatology Department of Dermatology University of Florida Click here for biography Michele Guadalupe, MPH Associate Director, Advocacy & Access National Eczema Association Click here for biography

Target Audience
The target audience consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
An action plan to enhance knowledge of clinical, economic, and humanistic burden of AD is needed by managed care and payer decision makers to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes. These health care professionals also need increased knowledge of recently approved and emerging AD therapies in order to develop and implement AD benefit design strategies that support an improvement in overall patient quality of life and clinical outcomes. This includes knowledge of the heterogeneity of the presentation of AD and the need to align specific therapies with specific patient types. Furthermore, it is clear that payers can benefit from dermatology providers’ experience and expertise when creating PA criteria in order to streamline utilization controls in order to improve patient access to appropriate therapy.

Educational Objectives
After completing this activity, the participant should be better able to:

• Discuss the impact of living with atopic dermatitis on patient and caregiver quality of life
• Describe atopic dermatitis treatment landscape and provider challenges
• Identify strategies that address barriers to care, improve patient quality of life, and support access to appropriate atopic dermatitis treatment
• Recognize health plan best practices and strategies for the management of atopic dermatitis

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER), the National Eczema Association and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-22-036-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, Medical Education Resources, Inc. identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Medical Education Resources, Inc. to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The NEA planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.